Knowledge HQ

The authors engineered high-potency CARs targeting HPV E6 peptide-MHC complexes. Primary T cells transduced with these CARs were expanded in 24-well G-Rex plates supplemented with IL-2. The optimized CARs showed comparable sensitivity and selectivity to clinical TCRs in cytotoxicity assays.

This study describes the use of universal antigen presenting cells (uAPC) to expand cord blood CAR-NK cells. G-Rex (M100 series) were used for GMP-grade expansion, enabling a closed system with optimal gas exchange. The process achieved robust expansion and enhanced antitumor activity of the NK cells.

The authors developed CAR-NK cells using the S309 antibody to target SARS-CoV-2. Primary S309-CAR-NK cells were expanded in G-Rex plates for 21 days following transduction. These cells demonstrated effective binding and killing of spike-protein expressing target cells in vitro.

This study reports the spontaneous generation of hyaline cartilage in hiPSC-derived multi-tissue organoids (MTOs) using a xeno- and feeder-free protocol. G-Rex100 were used to culture organoids for up to 30 weeks, overcoming hypoxia limitations. RNA-seq links cartilage formation to BMP signaling.

The authors tracked 89Zr-oxine labeled CAR-T cells targeting lymphoma using PET/MRI. Primary T cells were transduced and expanded in G-Rex plates. The study demonstrated dose-dependent tumor accumulation and transient lung retention followed by liver/spleen migration.

This study investigated combining GD2-CAR T cells with the MEK inhibitor trametinib for neuroblastoma. PiggyBac-generated CAR-T cells were expanded in G-Rex 6-well plates. The combination improved antitumor efficacy in vivo, overcoming MEK inhibitor-induced T cell suppression seen in vitro.

The authors developed DL4-conjugated microbeads to induce T cell differentiation from CD34+ stem cells without stromal cells. The system was adaptable to G-Rex plates for scalable production. It successfully generated proT cells capable of thymic engraftment and maturation.

This phase 1/2 trial evaluated virus-specific T cells (VSTs) for adenovirus infection post-transplant. VSTs were manufactured using G-Rex 10-M devices for 11-12 days. The therapy was highly effective (81% response rate), and efficacy correlated with Class II HLA restriction.

The authors developed Virus Induced Lymphocytes (VIL) for COVID-19 using artificial APCs (VIPR particles). G-Rex plates were used to facilitate rapid expansion (7 days) of SARS-CoV-2 specific T cells. The resulting VILs showed a polyfunctional cytokine profile and effector memory phenotype.

This study used a KPROR1 lung cancer model to show that immunogenic chemotherapy (Ox/Cy) enhances ROR1 CAR-T cell infiltration. Clinical human ROR1 CAR-T cells were expanded in G-Rex. The combination of Ox/Cy, CAR-T, and anti-PD-L1 improved survival.

The study combines oncolytic adenovirus (CAdTrio) with HER2-CAR T cells to treat pancreatic cancer. NK cells, expanded in G-Rex devices with feeder cells, were also used in experiments. The combination therapy modulated the tumor microenvironment and improved CAR-T infiltration and efficacy.

This paper outlines the CARAMBA clinical trial for SLAMF7 CAR-T cells generated via Sleeping Beauty transposon. The GMP manufacturing process utilizes G-Rex culture for the expansion of CAR-T cells over 12 days. This is the first clinical trial using advanced Sleeping Beauty technology.